426 related articles for article (PubMed ID: 10427468)
1. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
[TBL] [Abstract][Full Text] [Related]
2. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.
Court MH
Methods Enzymol; 2005; 400():104-16. PubMed ID: 16399346
[TBL] [Abstract][Full Text] [Related]
3. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
4. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
5. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
6. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
[TBL] [Abstract][Full Text] [Related]
7. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
[TBL] [Abstract][Full Text] [Related]
8. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.
Burchell B; Soars M; Monaghan G; Cassidy A; Smith D; Ethell B
Toxicol Lett; 2000 Mar; 112-113():333-40. PubMed ID: 10720749
[TBL] [Abstract][Full Text] [Related]
9. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age.
Allegaert K; Vanhaesebrouck S; Verbesselt R; van den Anker JN
Ther Drug Monit; 2009 Aug; 31(4):411-5. PubMed ID: 19494793
[TBL] [Abstract][Full Text] [Related]
10. Drug glucuronidation by human renal UDP-glucuronosyltransferases.
McGurk KA; Brierley CH; Burchell B
Biochem Pharmacol; 1998 Apr; 55(7):1005-12. PubMed ID: 9605424
[TBL] [Abstract][Full Text] [Related]
11. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.
Burchell B; Brierley CH; Rance D
Life Sci; 1995; 57(20):1819-31. PubMed ID: 7475929
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes.
Rouguieg K; Picard N; Sauvage FL; Gaulier JM; Marquet P
Drug Metab Dispos; 2010 Jan; 38(1):40-5. PubMed ID: 19841060
[TBL] [Abstract][Full Text] [Related]
13. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Nagar S; Remmel RP
Oncogene; 2006 Mar; 25(11):1659-72. PubMed ID: 16550166
[TBL] [Abstract][Full Text] [Related]
14. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol.
Ebner T; Remmel RP; Burchell B
Mol Pharmacol; 1993 Apr; 43(4):649-54. PubMed ID: 8474433
[TBL] [Abstract][Full Text] [Related]
15. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
Guillemette C; Lévesque É; Rouleau M
Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
[TBL] [Abstract][Full Text] [Related]
17. Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.
Di YM; Chan E; Wei MQ; Liu JP; Zhou SF
AAPS J; 2009 Sep; 11(3):469-80. PubMed ID: 19572200
[TBL] [Abstract][Full Text] [Related]
18. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.
Stone AN; Mackenzie PI; Galetin A; Houston JB; Miners JO
Drug Metab Dispos; 2003 Sep; 31(9):1086-9. PubMed ID: 12920162
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.
Mackenzie PI; Miners JO; McKinnon RA
Clin Chem Lab Med; 2000 Sep; 38(9):889-92. PubMed ID: 11097345
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms.
Sakaguchi K; Green M; Stock N; Reger TS; Zunic J; King C
Arch Biochem Biophys; 2004 Apr; 424(2):219-25. PubMed ID: 15047194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
